Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 94

1.

Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells.

Wang J, Yang DH, Yang Y, Wang JQ, Cai CY, Lei ZN, Teng QX, Wu ZX, Zhao L, Chen ZS.

Int J Mol Sci. 2020 Feb 19;21(4). pii: E1387. doi: 10.3390/ijms21041387.

2.

Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells.

Wang JQ, Li JY, Teng QX, Lei ZN, Ji N, Cui Q, Zeng L, Pan Y, Yang DH, Chen ZS.

Cancers (Basel). 2020 Feb 18;12(2). pii: E466. doi: 10.3390/cancers12020466.

3.

Overexpression of ABCG2 confers resistance to pevonedistat, an NAE inhibitor.

Wei LY, Wu ZX, Yang Y, Zhao M, Ma XY, Li JS, Yang DH, Chen ZS, Fan YF.

Exp Cell Res. 2020 Jan 20:111858. doi: 10.1016/j.yexcr.2020.111858. [Epub ahead of print]

PMID:
31972220
4.

Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance.

Wu ZX, Yang Y, Teng QX, Wang JQ, Lei ZN, Wang JQ, Lusvarghi S, Ambudkar SV, Yang DH, Chen ZS.

Cancers (Basel). 2020 Jan 12;12(1). pii: E186. doi: 10.3390/cancers12010186.

5.

Application of Immunohistochemistry in Basic and Clinical Studies.

Li A, Yang DH.

Methods Mol Biol. 2020;2108:43-55. doi: 10.1007/978-1-0716-0247-8_4.

PMID:
31939169
6.

Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.

Gupta P, Zhang GN, Barbuti AM, Zhang X, Karadkhelkar N, Zhou J, Ding K, Pan J, Yoganathan S, Yang DH, Chen ZS.

Cancer Lett. 2020 Mar 1;472:132-141. doi: 10.1016/j.canlet.2019.11.040. Epub 2019 Dec 11.

PMID:
31837444
7.

Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression.

Liao D, Zhang W, Gupta P, Lei ZN, Wang JQ, Cai CY, Vera AA, Zhang L, Chen ZS, Yang DH.

Molecules. 2019 Nov 30;24(23). pii: E4383. doi: 10.3390/molecules24234383.

8.

WB-PBPK approach in predicting zidovudine pharmacokinetics in preterm neonates.

Wei L, Mansoor N, Khan RA, Czejka M, Ahmad T, Ahmed M, Ali M, Yang DH.

Biopharm Drug Dispos. 2019 Nov;40(9):341-349. doi: 10.1002/bdd.2208. Epub 2019 Nov 28.

PMID:
31693190
9.

Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells.

Cui Q, Cai CY, Wang JQ, Zhang S, Gupta P, Ji N, Yang Y, Dong X, Yang DH, Chen ZS.

Int J Mol Sci. 2019 Aug 22;20(17). pii: E4095. doi: 10.3390/ijms20174095.

10.

Editorial: Novel Targets and Biomarkers in Solid Tumors.

Shi Z, Guo HQ, Cohen PA, Yang DH.

Front Pharmacol. 2019 Jul 26;10:828. doi: 10.3389/fphar.2019.00828. eCollection 2019. No abstract available.

11.

Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study.

Ji N, Yang Y, Cai CY, Wang JQ, Lei ZN, Wu ZX, Cui Q, Yang DH, Chen ZS, Kong D.

Front Oncol. 2019 Jun 18;9:514. doi: 10.3389/fonc.2019.00514. eCollection 2019.

12.

Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells.

Cui Q, Cai CY, Gao HL, Ren L, Ji N, Gupta P, Yang Y, Shukla S, Ambudkar SV, Yang DH, Chen ZS.

Front Oncol. 2019 Apr 25;9:313. doi: 10.3389/fonc.2019.00313. eCollection 2019.

13.

PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma.

Eze N, Lee JW, Yang DH, Zhu F, Neumeister V, Sandoval-Schaefer T, Mehra R, Ridge JA, Forastiere A, Chung CH, Burtness B.

Oral Oncol. 2019 Apr;91:69-78. doi: 10.1016/j.oraloncology.2019.02.026. Epub 2019 Mar 4.

14.

Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible.

Cui Q, Yang Y, Ji N, Wang JQ, Ren L, Yang DH, Chen ZS.

Future Med Chem. 2019 Feb 25. doi: 10.4155/fmc-2018-0403. [Epub ahead of print]

PMID:
30802141
15.

Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck.

Lee JW, Parameswaran J, Sandoval-Schaefer T, Eoh KJ, Yang DH, Zhu F, Mehra R, Sharma R, Gaffney SG, Perry EB, Townsend JP, Serebriiskii IG, Golemis EA, Issaeva N, Yarbrough WG, Koo JS, Burtness B.

Clin Cancer Res. 2019 Jun 1;25(11):3430-3442. doi: 10.1158/1078-0432.CCR-18-0440. Epub 2019 Feb 12.

16.

Y6, an Epigallocatechin Gallate Derivative, Reverses ABCG2-Mediated Mitoxantrone Resistance.

Zhao RQ, Wen Y, Gupta P, Lei ZN, Cai CY, Liang G, Yang DH, Chen ZS, Xie YA.

Front Pharmacol. 2019 Jan 10;9:1545. doi: 10.3389/fphar.2018.01545. eCollection 2018.

17.

Discovery of Novel Quinoline-Chalcone Derivatives as Potent Antitumor Agents with Microtubule Polymerization Inhibitory Activity.

Li W, Xu F, Shuai W, Sun H, Yao H, Ma C, Xu S, Yao H, Zhu Z, Yang DH, Chen ZS, Xu J.

J Med Chem. 2019 Jan 24;62(2):993-1013. doi: 10.1021/acs.jmedchem.8b01755. Epub 2018 Dec 24.

PMID:
30525584
18.

Modulating ROS to overcome multidrug resistance in cancer.

Cui Q, Wang JQ, Assaraf YG, Ren L, Gupta P, Wei L, Ashby CR Jr, Yang DH, Chen ZS.

Drug Resist Updat. 2018 Nov;41:1-25. doi: 10.1016/j.drup.2018.11.001. Epub 2018 Nov 14. Review.

PMID:
30471641
19.

Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.

Ji N, Yang Y, Lei ZN, Cai CY, Wang JQ, Gupta P, Xian X, Yang DH, Kong D, Chen ZS.

Biochem Pharmacol. 2018 Dec;158:274-285. doi: 10.1016/j.bcp.2018.10.028. Epub 2018 Oct 26.

PMID:
30431011
20.

VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters.

Ji N, Yang Y, Cai CY, Lei ZN, Wang JQ, Gupta P, Teng QX, Chen ZS, Kong D, Yang DH.

Front Pharmacol. 2018 Oct 30;9:1236. doi: 10.3389/fphar.2018.01236. eCollection 2018.

Supplemental Content

Loading ...
Support Center